TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
ROIV

Roivant Sciences Ltd

Healthcare · Biotechnology

35.80$ -0.9% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Cash Flow

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Cash Flow ROIV
Line item 2019 2020 2021 2022 2023 2024 2025 2026
-44,071.8% -1,125.5% -2,320.4% -1,225.9% -2,674.9% -2,339.3% -2,889.4% -9,084.1%
– 8.8% 24.9% 10.7% 59.8% 67.4% 48.4% 40.5%
2,532.7% 181.1% 357.0% 1,021.9% 690.7% 610.2% 994.8% 4,190.9%
-1,342.8% -2,913.7% 619.1% 402.1% 874.9% – – –
2,137.4% 22.6% 302.3% 28.4% 20.1% 58.2% -265.2% -7,527.8%
490.4% 7.3% 24.4% 31.5% 40.2% 4.2% 15.8% 99.4%
-2,478.8% 2,503.8% -133.2% 548.6% -140.4% 15,906.9% -6,079.5% -8,260.7%
– – – – 516.1% 18.3% – –
-317.3% -1,755.8% -0.5% – 1.0% 2.9% -4,451.3% -3,868.1%
7,566.1% 76.4% 62.2% 26.8% 411.5% -93.9% -181.6% 0.0%
33,004.2% 320.8% 1,917.5% 554.9% 1,584.1% 1,281.9% -4,198.5% 1,625.1%
48,155.4% 1,973.6% -536.1% -123.8% -1,211.3% 14,851.4% -13,164.9% -15,674.1%
-44,562.2% -1,132.8% -2,344.8% -1,257.4% -2,715.1% -2,343.6% -2,905.2% -9,183.5%

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?